Recent Progress in Polynuclear Ruthenium Complex-Based DNA Binders/Structural Probes and Anticancer Agents.

Area of Science:

• Coordination Chemistry
• Medicinal Chemistry
• Biochemistry

Background:

• Mononuclear ruthenium complexes like NAMI-A and TLD-1433 show promise in clinical trials as anticancer agents.
• Polynuclear ruthenium complexes offer synergistic effects, enhancing DNA interaction and anticancer efficacy.
• Ruthenium complexes are explored as alternatives to cisplatin for cancer treatment.

Purpose of the Study:

• To review representative polynuclear ruthenium complexes developed over recent decades.
• To categorize these complexes based on their structure (homo- vs. hetero-nuclear) and bridging ligands (rigid vs. flexible).
• To highlight their roles as DNA structural probes, DNA binders, and in vitro anticancer agents.

Main Methods:

• Literature review of polynuclear ruthenium complexes.
• Categorization based on nuclearity (homo- and hetero-polynuclear).
• Classification based on bridging ligand type (rigid and flexible).

Main Results:

• Overview of various polynuclear ruthenium complexes with DNA-binding and anticancer properties.
• Discussion of structure-activity relationships in these complexes.
• Identification of complexes acting as DNA structural probes and binders.

Conclusions:

• Polynuclear ruthenium complexes exhibit significant potential in cancer therapy.
• Structural diversity, including bridging ligands, influences their biological activity.
• Further investigation into these complexes is warranted for developing novel anticancer drugs.